ClinicalTrials.gg
Not yet recruitingNCT07239440Updated Nov 20, 2025

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A Phase 2 interventional study of DA-2811 and DA-2811-C in Diabete Mellitus, sponsored by Dong-A ST Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Dong-A ST Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 224 studies in Diabetes Mellitus with a site in Korea, Republic of — 22 open to participants now, 25 under way, 3 of them phase 3. Diabetes Mellitus · Korea, Republic of.

Planned enrollment
68th of 181
288 · median 140
Started
2025
with 8 others
Phase 2
6 of 224
2 open now
Primary completion
2026-12
later than 14 of 24 live
Registered
217th of 224
by date

Among the 224 studies in Diabetes Mellitus with a site in Korea, Republic of, this one is the 68th largest by planned enrollment of the 181 interventional ones that give a count, is one of 9 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 14 of the 24 other live ones, and was the 217th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

22 of the 224 studies in Diabetes Mellitus with a site in Korea, Republic of are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Diabetes Mellitus with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control

03

Conditions studied

  • Diabete Mellitus

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type II diabetes mellitus aged 19 years or older
  2. Patients with fasting plasma glucose≤270mg/dL at the screening visit
  3. Patients with 18.5kg/m\^2≤≤40kg/m\^2 at the screening visit
  4. Patients who have signed an themselves after receiving detailed explanation about the clinical study

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
  2. Patients with a medical history of (NYHA) class III\~IV heart failure or with congestive heart failure, acute and unstable heart failure
  3. Patients with severe infectious disease or severe traumatic systemic disorders
  4. Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia
  5. Patients with galactose intolerance, lapp lactase deficiency, glucosegalactose malabsorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    DA-2811

    DA-2811 + DA-2811-R2

    Drug: DA-2811

  • Experimental
    DA-2811-C

    DA-2811-C + DA-2811-R1

    Drug: DA-2811-C

Interventions

  • DA-2811 + DA-2811-R2, orally, once daily

  • DA-2811-C + DA-2811-R1, orally, once daily

06

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: Change from baseline at 12 weeks

Secondary outcomes

  1. HbA1c

    Time frame: Change from baseline at 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2026, 13 months later.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 13 months is close to that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartEst.
Nov 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07239440
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Nov 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-2811

Start the discussion